Novel prognostic biomarkers, whether clinical, circulating or coming from imaging techniques, are continuously proposed for risk stratification in coronary artery disease (CAD), but only a very few have entered routine clinical practice. Left ventricular ejection fraction (LVEF) is the simplest and most widespread parameter to measure left ventricular (LV) systolic dysfunction and the main driver for categorising heart failure (HF). Although LVEF has many acknowledged limitations, it is still pivotal for the management, risk stratification and follow-up of patients with cardiovascular diseases, being easy to obtain and non-invasive. Its crude value per se drives essential therapeutic intervention in HF, such as drugs for neurohormonal antagonism or a defibrillator for primary prevention. Traditionally, patients with HF have been divided into those with heart failure and reduced LVEF (HFrEF) and preserved LVEF (HFpEF) with variable cut-points ranging from 40-50%. The HFrEF group tends to be younger with a higher rate of CAD than the HFpEF group. The 2016 European Society of Cardiology guidelines on HF officially introduced a new HF phenotype, 1 when LVEF is comprised between 40-49%, termed 'HFmrEF', which mostly represents an intermediate phenotype, with a CAD prevalence similar to that observed in HFrEF. 2 In the present issue of the Journal, Siontis and colleagues provide further evidence that LV systolic function, as estimated by LVEF, holds prognostic value in patients referred for coronary artery percutaneous intervention (PCI), independently of the clinical presentation, either acute or stable.
3 The authors analysed patient-level data from 6198 subjects enrolled in five randomised clinical trials, who were classified into three groups according to LVEF (reduced, <40%; mid-range, 40-49%; preserved, 50%). Briefly, irrespective of the clinical setting, patients in the reduced and mid-range groups displayed higher all-cause and cardiac mortality and were at increased risk for the composite of cardiac death, stroke and myocardial infarction along a five-year follow-up. They also report that the Harrel's C comparison for the adjusted model, showed the best cut-off of LVEF for the midrange to reduced LVEF group was 35%, lower than that proposed by the latest guidelines for the management of heart failure. 1 The population studied for the aims of the present analysis was not composed exclusively of patients with a clinical diagnosis of heart failure, thus a significant increase in risk may be observed at lower LVEF cut-points.
In the era of precision medicine and of tailored therapy and prognostic assessment, one may wonder why we should keep relying on LVEF, which has been amongst the tools of the cardiologist for decades, to predict the outcome of patients referred to PCI. A number of reasons exist, indeed. First, LVEF is expressed by a single number, which makes it easy to interpret and suitable for classifications; second it can be easily measured and re-assessed in each single patient; third, some therapeutic choices resulting from clinical trials (e.g. regarding the use of drugs for neurohormonal antagonism) are driven by the extent of LV systolic dysfunction estimated by LVEF. 1 Still, there are some pathophysiological arguments for an underrating of LVEF as a reliable index of systolic function. 4 Moreover, the degree of the impairment in LV systolic function provides information about the extent of the damage directed to the myocardium, while it is not a clue to the underlying cause. 5 In the cohort considered in the study by Siontis et al., the cause of myocardial damage was likely homogeneous (ischaemic heart disease), and thus more severe damage (as expressed by a lower LVEF) corresponded to a worse patient prognosis. The much larger proportion of patients with previous history of heart failure in the reduced ejection fraction (EF) group (24%) compared to patients in the preserved and mid-range (2% and 6%, respectively), also suggests that a pre-existing LV dysfunction may have impacted on the outcome. With this regard, an analysis on the trajectory of LVEF over time in patients treated with PCI and of its interaction with cardiovascular events is of extreme interest, as indeed patients with impaired LVEF undergoing revascularization are thought to represent a large part of those with 'recovered ejection fraction'. 6 Another possible confounder in the interpretation of the present results, could be the influence of time from symptom onset to revascularization on the degree of functional recovery, at least in the acute setting.
Assessment of LV systolic function is bound to remain a key element in patient prognostication in the next years. With this respect, a refinement in the evaluation of LV systolic function could be achieved by using global longitudinal strain, 7, 8 overcoming some limitations linked to LVEF measurements like geometric assumptions and technical issues, such as apical foreshortening and difficulties in proper delineation of the endocardial borders. Nonetheless, to further reduce morbidity and mortality of patients with CAD, it seems likely that we need to introduce into clinical practice some novel markers, possibly linked to therapeutic optimization either in the peri-procedural and in the chronic setting.
Declaration of conflicting interests
The author(s) declared no potential conflicts of interest with respect to the research, authorship and/or publication of this article.
